Related Experiment Videos
Passive local immunotherapy of experimental staphylococcal pneumonia with human intravenous immunoglobulin
F Ramisse1, M Szatanik, P Binder
1Centre d'Etudes du Bouchet, Vert Le Petit, France.
Abstract:
Staphylococcus aureus remains a life-threatening agent of nosocomial pneumonia in immunocompromised patients. The increasing incidence of strains exhibiting wide-spectrum resistance to antibiotics, such as methicillin-resistant S. aureus (MRSA), requires new therapeutic strategies. There is renewed interest in passive immunization with human plasma-derived immunoglobulins (IVIG) as antiinfective agents. The efficacy of IVIG was tested in an experimental model of staphylococcal pneumonia, using both an MRSA clinical isolate and reference strain Cowan III, in mice immunosuppressed with cyclophosphamide. Efficient antistaphylococcal activities were obtained with IVIG administered intravenously or intranasally. IVIG saturated with protein A or its F(ab')2 fragments were as efficient as intact IVIG, suggesting that protection did not require opsonization through IgG Fc-phagocyte Fc gamma-receptor interactions. Thus, topical administration of IVIG may replace a local antibody response to S. aureus in an immunocompromised host and may be useful in prophylaxis and treatment of nosocomial S. aureus pneumonia.
Insights
Intravenous immunoglobulin (IVIG) shows promise in treating Staphylococcus aureus pneumonia, especially antibiotic-resistant strains like MRSA. Topical IVIG may offer a new therapeutic strategy for immunocompromised patients.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Staphylococcus aureus is a significant cause of nosocomial pneumonia, particularly in immunocompromised individuals.
- Rising antibiotic resistance, exemplified by methicillin-resistant S. aureus (MRSA), necessitates novel therapeutic approaches.
- Passive immunization using human plasma-derived immunoglobulins (IVIG) is being re-evaluated for anti-infective properties.
Purpose of the Study:
- To evaluate the efficacy of IVIG in an experimental model of staphylococcal pneumonia.
- To investigate the therapeutic potential of IVIG against both MRSA and a reference S. aureus strain.
- To explore the mechanism of IVIG's protective effects, including the role of Fc-mediated interactions.
Main Methods:
- An experimental pneumonia model was established in cyclophosphamide-immunosuppressed mice.
- Mice were infected with either an MRSA clinical isolate or the S. aureus reference strain Cowan III.
- Intravenous and intranasal administration of IVIG, as well as IVIG saturated with protein A or F(ab')2 fragments, were tested.
Main Results:
- Both intravenous and intranasal administration of IVIG demonstrated efficient antistaphylococcal activity.
- IVIG saturated with protein A or its F(ab')2 fragments exhibited efficacy comparable to intact IVIG.
- These findings suggest that the protective mechanism of IVIG may not solely rely on Fc-mediated opsonization.
Conclusions:
- Topical administration of IVIG can effectively combat S. aureus pneumonia in an immunocompromised setting.
- IVIG may serve as a valuable prophylactic and therapeutic agent for nosocomial S. aureus pneumonia.
- The study highlights a potential non-opsonic mechanism for IVIG's anti-staphylococcal action.